GENEWIZ is fully committed to advancing research around the novel coronavirus (2019-nCoV/SARS-CoV-2) outbreak. Our global presence, state-of-the-art facilities, and highly qualified scientific team, allows us to deliver with unparalleled quality and excellence. GENEWIZ’s unique DNA sequencing and synthesis solutions help research institutions around the world to better understand this pandemic virus.
De novo gene synthesis technologies enable the development and optimization of antigen-presenting viral genes for safe and rapid vaccine development. GENEWIZ’s synthetic DNA solutions can also be utilized to rapidly produce standard/controls for the development of coronavirus diagnostic assays.
Scientists can now order primers and qPCR probes approved by the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Chinese government for rapid identification of the virus.
Please see the available list of primers and qPCR probes here. HPLC purified COVID-19 primers and qPCR probes are available for direct order through our e-commerce platform. Note, all primers and qPCR probes are Research Use Only (RUO) and not for use in diagnostics.
Next Generation Sequencing
NGS continues to play an indispensable role in characterizing and understanding the rapid spread of the coronavirus across the globe. Technologies such as whole genome sequencing and targeted amplicon sequencing can help discover, identify, and monitor pathogenic sequences.
GENEWIZ’s NGS service portfolio is uniquely positioned to help you identify and uncover known and emerging viruses.
PCR + Sanger Services
GENEWIZ’s PCR + Sanger workflows enable the research community to understand emerging infections and advance vaccine development at the RUO level. These assays can facilitate basic research, cell line development and characterization, viral genome confirmation, antibody HC/LC confirmation, and more.
Our GLP services comply with 21 CFR, Part 58, and use PCR + Sanger sequencing to assist with the preclinical development, clinical trials, and post-manufacturing phases of therapeutics and vaccine development pipelines. Among these, we offer GLP-compliant plasmid preparation, plasmid sequence confirmation, viral genome verification, and gDNA/cDNA/RNA confirmation.
GENEWIZ's CAP-accredited and CLIA-certified clinical laboratory operates NGS and Sanger workflows to support clinical trials.
Our CLIA-certified services include pre-validated whole genome and exome sequencing, as well as custom validations.
Our CLIA environment capabilities include RNA-Seq, metagenomics, and variant confirmation RUO workflows in a CLIA environment.
- US Centers for Disease Control and Prevention (2020, March 30). CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. https://www.fda.gov/media/134922/download.
- Author Unknown. (2020, January 17). Diagnostic detection of 2019-nCoV by real-time RT-PCR. https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2.
- National Institute For Viral Disease Control and Prevention. (2020, January 21). Specific primers and probes for detection 2019 novel coronavirus. http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html.
Additional information can be found at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance